The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
L-Carnitine is not a peptide. Including it in The Peptide Bible requires a brief explanation — and then a substantive reason why the explanation is worth providing.
L-Carnitine was first isolated from meat extracts in 1905 by two independent research groups (Gulewitsch and Krimberg in Germany, and Kutscher). The name derives from the Latin carnis (meat/flesh), reflecting its dietary source. Its biochemical function as a carrier molecule for long-chain fatty acids was established through decades of enzymological research, culminating in the 1950s work of Fritz and colleagues who documented the carnitine-acylcarnitine translocase system in mitochondria. The conditionally essential nature of carnitine — produced endogenously from lysine and methionine but also substantially obtained from diet, with deficiency occurring in specific disease states — was established through observations in patients on hemodialysis (who cannot synthesize carnitine adequately due to renal dysfunction) and in patients with genetic primary carnitine deficiency disorders.
The reason for inclusion in this book: L-Carnitine is ubiquitous in the community that uses the peptides covered elsewhere in this text. It appears in essentially every athletic supplement stack, every longevity protocol review, and virtually every metabolic/mitochondrial optimization discussion. Its forms (particularly ALCAR for cognitive goals) are frequently combined with nootropic peptides. Its fat oxidation mechanism is invoked alongside GH secretagogues and other metabolic compounds. And the clinical evidence base — both the strong evidence and the weak evidence — is routinely misunderstood in community discussions. A chapter that accurately characterizes what L-Carnitine does well (neuropathy, PAD, cardiac, infertility) versus where it underdelivers (fat loss in healthy adults) versus where the wrong form is commonly used (cognitive goals with plain carnitine instead of ALCAR) is a meaningful contribution to evidence-based self-application.
THE CENTRAL TENSION
L-Carnitine has been evaluated in hundreds of randomized controlled trials — one of the largest clinical trial evidence bases of any compound in this book. The evidence shows genuine, Grade B results for specific pathological conditions: ALCAR for neuropathy and cognitive aging; PLCAR for peripheral artery disease; LCLT for muscle recovery and androgen receptor upregulation; plain L-carnitine for male infertility and cardiac outcomes in post-MI patients. None of these benefits extend reliably to healthy adults seeking fat loss or performance enhancement, who represent the majority of the supplement market. The form matters enormously — using plain L-carnitine for cognitive goals (a common community practice) is using a compound that cannot cross the blood-brain barrier for a goal that requires CNS penetration. The TMAO safety signal complicates the cardiovascular framing: a compound marketed for cardiac health has a metabolic pathway that produces a pro-atherogenic metabolite. The evidence base is large, real, and substantially misapplied.
The TMAO concern fundamentally changed how carnitine should be discussed in the context of cardiovascular health. A compound marketed for heart health has a metabolic pathway that generates a pro-atherogenic metabolite. This paradox requires honest treatment.
Koeth RA et al. (2013, Nature Medicine): the landmark paper establishing the carnitine-TMAO-atherosclerosis pathway. Key findings: (1) Dietary L-carnitine is metabolized by specific gut bacteria (primarily Firmicutes and certain Proteobacteria) to TMA (trimethylamine); (2) TMA is absorbed and converted in the liver by FMO3 (flavin monooxygenase 3) to TMAO (trimethylamine N-oxide); (3) TMAO promotes macrophage foam cell formation in arterial walls by inhibiting reverse cholesterol transport and promoting scavenger receptor expression — direct pro-atherogenic mechanisms; (4) In the study population, L-carnitine feeding in omnivores with gut microbiomes capable of producing TMAO correlated with atherosclerosis extent; vegans (with different gut microbiomes generating less TMAO from carnitine) showed reduced TMAO generation; (5) Suppression of gut bacteria with antibiotics reduced TMAO generation from carnitine. This paper established the biological pathway; it did not establish clinical dose-dependent cardiovascular risk from supplemental carnitine specifically.
Zhao et al. (2022, BMC Medicine): Mendelian randomization study using genetic variants to predict L-carnitine levels and estimate unconfounded causal associations with cardiovascular disease. Key finding: genetically predicted higher L-carnitine was associated with higher risk of coronary artery disease overall (OR 1.07, 95% CI 1.02-1.11) and specifically in men (OR 1.09, 95% CI 1.02-1.16), with a null association in women (OR 1.00). These associations were robust to different analysis methods. Mendelian randomization avoids the confounding that limits observational studies — it uses genetic variants as proxies for lifetime carnitine exposure, substantially reducing reverse causation and confounding biases. Conclusions: 'Our findings do not support a beneficial association of L-carnitine with CVD and its risk factors but suggest potential harm.' The sex-specific finding (risk in men, null in women) is unexplained and may reflect sex differences in TMAO metabolism or FMO3 activity. This is the strongest current evidence for a causal cardiovascular concern from elevated L-carnitine.
THE TMAO SAFETY ASSESSMENT — CALIBRATED FOR COMMUNITY USE
The TMAO signal should be acknowledged but proportioned appropriately. What is established: (1) L-carnitine → TMAO is a real biological pathway; (2) TMAO has pro-atherogenic mechanisms at the cellular level; (3) Mendelian randomization suggests genetically higher L-carnitine is associated with modestly higher CAD risk (OR 1.07); (4) The risk signal appears primarily in men. What is not established: (1) Whether supplemental L-carnitine at typical doses (1-3g/day) produces clinically meaningful TMAO elevations vs dietary carnitine from red meat; (2) Whether the Mendelian randomization finding (genetically predicted lifetime exposure) translates to short-term supplementation courses; (3) Whether the OR 1.07 is clinically meaningful in absolute terms for individual risk. THE PRACTICAL CALIBRATION: The TMAO concern is most relevant for: (a) individuals with existing cardiovascular risk (multiple risk factors, family history, elevated baseline TMAO); (b) long-term high-dose supplementation with plain L-carnitine; (c) men more than women. ALCAR has substantially lower TMAO production vs plain L-carnitine due to faster intestinal absorption reducing gut bacterial exposure — making ALCAR the preferred form from a cardiovascular safety standpoint for most applications. The benefit-risk ratio for L-carnitine in hemodialysis, post-MI cardiac patients, PAD, or male infertility (where genuine benefit is established) is different from the benefit-risk ratio in healthy carnitine-replete adults seeking fat loss (where benefit is marginal at best).
L-Carnitine: (R)-3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propan-aminium hydroxide. MW 161.20 Da. Chemical formula C₇H₁₅NO₃. Zwitterionic at physiological pH — the carboxylate group (pKa ~3.8) is deprotonated and the quaternary ammonium group is permanently positively charged. This zwitterionic structure makes L-carnitine highly water-soluble and limits passive diffusion across lipid bilayers — explaining its poor CNS penetration. Synthesized from lysine and methionine via a 4-enzyme pathway primarily in the liver and kidneys. Requires ascorbic acid (vitamin C), niacin, vitamin B6, and iron as cofactors. Dietary sources: beef (~95 mg/100g), lamb (~78 mg/100g), pork (~28 mg/100g), chicken (~5 mg/100g). Plant foods: essentially zero. This dietary distribution explains why vegans and vegetarians typically have carnitine pools 25-50% lower than omnivores.
Form
Structure
BBB Crossing
Half-Life
Primary Clinical Use
L-Carnitine (LCNC)
Base compound; zwitterionic
Poor — highly water-soluble, limited lipid bilayer permeability
~15 hours (oral, single dose)
Fat transport; male infertility; cardiac; hemodialysis
A (dialysis), B (infertility, cardiac)
Acetyl-L-Carnitine (ALCAR)
N-acetyl ester of L-carnitine; more lipophilic
Yes — significantly better CNS penetration due to increased lipophilicity
~4-6 hours (faster clearance)
Neuroprotection; cognitive aging; neuropathy; mitochondrial support; ALCAR-specific: donates acetyl groups for AcCoA/ACh synthesis
B (neuropathy, cognitive aging)
L-Carnitine L-Tartrate (LCLT)
L-carnitine salt of tartaric acid (2:1 LCLT:tartrate); fastest absorption
Poor (same limitations as LCNC)
Similar to LCNC, rapid peak
Exercise recovery; androgen receptor upregulation; muscle damage reduction; post-exercise immune
B (recovery, AR upregulation — Volek 2002)
Propionyl-L-Carnitine (PLCAR)
Propionyl ester; provides propionyl group for Krebs cycle and NO synthesis
Moderate
Similar to LCNC
Peripheral artery disease; intermittent claudication; vascular endothelial function; erectile dysfunction
B (PAD walking distance meta-analysis)
THE FORM-FUNCTION MATCHING RULE
The most important clinical principle in L-Carnitine pharmacology: match the form to the intended goal. COGNITIVE FUNCTION, NEUROPROTECTION: ALCAR only — plain L-carnitine cannot cross the BBB in meaningful amounts; using plain L-carnitine for cognitive goals is pharmacologically incorrect. PERIPHERAL ARTERY DISEASE, VASCULAR FUNCTION, PAD: PLCAR specifically — the propionyl group provides substrate for NO synthesis and Krebs cycle entry; plain L-carnitine lacks this vascular-specific mechanism. EXERCISE RECOVERY, ANDROGEN RECEPTOR UPREGULATION: LCLT specifically — fastest absorption matters for post-exercise window; Volek 2002 specifically used LCLT; results may not transfer to other forms. MALE INFERTILITY, CARDIAC OUTCOMES, GENERAL METABOLIC, HEMODIALYSIS: Plain L-carnitine (LCNC) or any form is appropriate — these effects occur at the peripheral level where BBB crossing is not required. Dozens of trials showing negative results for 'carnitine' for cognitive goals used plain L-carnitine — the wrong form for the goal.
The defining biochemical function of L-carnitine: carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane esterifies long-chain fatty acyl-CoA with carnitine to form acylcarnitine; the acylcarnitine is transported across the inner mitochondrial membrane by the carnitine-acylcarnitine translocase (CACT); carnitine palmitoyltransferase II (CPT-II) on the inner membrane releases carnitine and regenerates acyl-CoA inside the mitochondrial matrix; the acyl-CoA enters beta-oxidation. Without carnitine, long-chain fatty acids cannot be oxidized for energy. This function is shared by all four forms and provides the theoretical basis for 'fat burning' claims — but the clinical reality is that healthy adults with normal carnitine status are not limited by carnitine availability for fat oxidation; the rate-limiting step is typically total caloric balance and hormonal milieu, not carnitine concentration.
Acetyl-L-carnitine's clinical superiority for CNS applications derives from specific mechanisms not available to other forms: (1) BBB crossing: the acetyl group increases lipophilicity, allowing ALCAR to cross the blood-brain barrier by passive diffusion; once inside the CNS, it is hydrolyzed to carnitine + acetyl-CoA. (2) Acetylcholine precursor: the acetyl group from ALCAR enters acetyl-CoA pools, which can be used by choline acetyltransferase to synthesize acetylcholine — the primary neurotransmitter for memory and learning. This cholinergic support is the proposed mechanism for ALCAR's cognitive benefits, which are particularly relevant in aging where acetylcholine synthesis declines. (3) Cardiolipin support: acetyl-CoA from ALCAR is used in the synthesis of cardiolipin, the unique phospholipid of the inner mitochondrial membrane that is essential for electron transport chain complex assembly and mitochondrial membrane integrity. Age-related cardiolipin decline impairs mitochondrial function; ALCAR supplementation may slow this decline. (4) NGF sensitivity: ALCAR upregulates nerve growth factor (NGF) receptor expression, enhancing neuronal responsiveness to NGF — providing additional neuroprotective and nerve regeneration support. (5) Oxidative stress reduction in brain tissue: aged rat studies show ALCAR (but not plain L-carnitine at equivalent doses) reduces lipid peroxidation markers (MDA) and oxidized nucleotides (oxo8dG) in hippocampal and cortical tissue.
Propionyl-L-carnitine's specific vascular benefits derive from the propionyl group: (1) Propionyl-CoA substrate: propionyl-CoA (from propionyl-L-carnitine hydrolysis) enters the Krebs cycle via succinate, bypassing the acetyl-CoA entry point; this provides metabolic substrate for ischemic or poorly perfused vascular tissue that may be metabolically limited. (2) Nitric oxide: PLCAR enhances endothelial nitric oxide synthase (eNOS) activity and NO production; NO is the primary endothelium-derived vasodilator; improved NO availability in ischemic peripheral vascular tissue reduces claudication pain and improves walking distance. (3) Reduced oxidative stress in ischemic tissue: PLCAR specifically reduces oxidative damage in ischemic peripheral vascular tissue — an effect not consistently shown with plain L-carnitine.
The most pharmacologically surprising finding in the L-carnitine literature: Volek et al. (2002) demonstrated that LCLT supplementation significantly increased androgen receptor (AR) concentration in skeletal muscle biopsy samples following resistance exercise. The proposed mechanism: L-carnitine increases muscle oxygen delivery (through enhanced fat oxidation and reduced hypoxia); improved oxygenation of muscle tissue enhances androgen receptor expression; more AR means better testosterone response to the same circulating testosterone concentrations. Critically — this is not a testosterone-raising effect. LCLT does not increase serum testosterone. It increases the density of receptors through which testosterone exerts its anabolic effects — a fundamentally different mechanism than anabolic steroids or testosterone administration. Additional LCLT findings in the same research program: reduced muscle damage markers (reduced creatine kinase, reduced muscle soreness scores); reduced free radical production post-exercise; improved exercise recovery timeline. The LCLT form specifically was used in this research; generalization to other forms is not established.
L-Carnitine's clinical evidence is simultaneously one of the largest in supplementation science and one of the most form-dependent. Understanding which evidence applies to which form is essential for interpreting the literature.
The most robust clinical evidence for any carnitine form in a CNS indication: Montgomery et al. meta-analysis (2003, Journal of Molecular Psychiatry): 21 randomized placebo-controlled trials of ALCAR for cognitive aging and mild cognitive impairment. Results: significant improvement in cognitive function measures compared to placebo across the pooled analysis; effects most pronounced in older adults with MCI (mild cognitive impairment); effects on memory, attention, and psychomotor performance all showing significant improvements. Grade B — large pooled dataset; consistent direction; quality of individual trials varies. For peripheral and diabetic neuropathy: multiple RCTs of ALCAR (1,500-3,000 mg/day) in patients with established neuropathy show significant improvements in pain scores, nerve conduction velocity, and nerve regeneration markers. A 2021 Cochrane review specifically for ALCAR in neuropathy confirmed clinically meaningful pain reduction and nerve function improvement. Grade B — Cochrane review quality; limited by heterogeneity of trial populations.
Propionyl-L-carnitine has been evaluated in multiple RCTs specifically for peripheral artery disease and intermittent claudication (leg pain during walking due to inadequate blood flow). Meta-analysis of PLCAR RCTs: average improvement in maximal walking distance of approximately 90-100 meters vs placebo — a clinically meaningful improvement for PAD patients who may have baseline maximal walking distances of 100-200 meters. The effect size is comparable to established PAD pharmacotherapy. Grade B — multiple small-medium RCTs with consistent direction; mechanistically well-characterized. For erectile dysfunction secondary to peripheral vascular disease: PLCAR combined with L-arginine shows effects on vascular-mediated erectile function, though not generalizable to neurogenic or psychological erectile dysfunction.
Volek JS et al. (2002, Journal of Strength and Conditioning Research): double-blind, crossover study in resistance-trained men receiving LCLT (2g/day) or placebo. Post-exercise muscle biopsy analysis: LCLT group showed significantly higher androgen receptor concentration in muscle tissue. Additional findings: reduced muscle damage markers (creatine kinase, DOMS); reduced free radical production post-exercise. The androgen receptor upregulation finding is Grade B — methodologically sound; independent mechanistic rationale; not yet replicated at scale. Stefan et al. (2021, Nutrients): 5-week LCLT supplementation (2g/day) in recreationally active men and women — improved exercise recovery metrics vs placebo (reduced DOMS, faster recovery of strength, reduced creatine kinase). The fast absorption of the tartrate salt specifically supports the post-exercise window application.
Male infertility: L-Carnitine is highly concentrated in the epididymis (where sperm mature) and is essential for sperm motility through its role in beta-oxidation of fatty acids for sperm flagellar energy. Multiple RCTs and a 2020 meta-analysis confirm L-carnitine supplementation (2-3g/day for 3-6 months) improves sperm motility, sperm concentration, and pregnancy rates in men with idiopathic infertility. Grade B — consistent across multiple independent RCTs; biologically plausible mechanism. Post-MI cardiac outcomes: DiNicolantonio et al. (2013, Mayo Clinic Proceedings): meta-analysis of 27 randomized controlled trials (n=3,629) in patients with acute MI or heart failure. L-Carnitine supplementation vs placebo: 27% reduction in all-cause mortality (RR 0.73); 40% reduction in ventricular arrhythmias; 25% reduction in angina. Grade B — large meta-analysis; substantial effect sizes; most evidence from ischemic/infarcted myocardium where carnitine depletion is a pathological feature.
L-Carnitine injection (Carnitor, FDA-approved) is indicated for the prevention and treatment of carnitine deficiency in patients on maintenance hemodialysis. Hemodialysis removes carnitine from blood more rapidly than it can be replaced, and dialysis patients develop genuine carnitine deficiency with associated skeletal muscle weakness, cardiac dysfunction, and dyslipidemia. Intravenous L-carnitine after dialysis sessions corrects deficiency and improves these outcomes. This is the one FDA-approved indication and represents Grade A evidence in the specific deficiency context. It is clinically distinct from supplementation in carnitine-replete healthy individuals.
The primary market claim for L-carnitine supplements — fat loss and body composition improvement in healthy adults — has the weakest evidence relative to the magnitude of commercial promotion. Multiple meta-analyses of L-carnitine for fat loss: effect sizes are small, inconsistent, and primarily observed in specific deficient or pathological populations (obesity with metabolic syndrome, type 2 diabetes, CKD). In healthy, carnitine-replete adults at caloric balance, additional carnitine does not increase fat oxidation — because carnitine is not the rate-limiting step in fatty acid metabolism under these conditions. The mechanistic argument ('more carnitine = more fat transport = more fat burning') ignores that transport capacity is not limiting when carnitine status is normal. Fat loss in healthy adults: Grade C — modest effect in deficient populations; essentially no meaningful effect in carnitine-sufficient healthy adults maintaining current caloric balance.
Form
Indication
Grade
Key Evidence
Honest Assessment
ALCAR
Cognitive aging/MCI
B
Montgomery 2003 (21-RCT meta-analysis); consistent improvement in cognitive measures
Most evidence-supported CNS carnitine application; requires ALCAR specifically
ALCAR
Peripheral/diabetic neuropathy
B
2021 Cochrane review; pain reduction + nerve conduction improvement
Cochrane-level evidence; ALCAR specifically required
LCLT
Exercise recovery
B
Volek 2002 (AR upregulation); Stefan 2021 (recovery metrics); multiple supporting studies
LCLT specifically; fastest absorption form for post-exercise window
PLCAR
Peripheral artery disease/claudication
B
Meta-analysis; ~90m walking distance improvement vs placebo
Clinically meaningful for PAD; requires PLCAR specifically for vascular mechanism
LCNC
Male infertility
B
2020 meta-analysis; improved sperm motility, concentration, pregnancy rates
Consistent evidence; 3-6 months treatment course needed
LCNC
Post-MI/heart failure cardiac
B
DiNicolantonio 2013 (27-RCT, 27% mortality reduction)
Strong meta-analysis; most relevant in ischemic/deficiency context
LCNC
Hemodialysis carnitine deficiency
A
FDA-approved; RCT evidence; pathological deficiency context
Only FDA-approved indication; not extrapolatable to healthy adults
LCNC/Any
Fat loss in healthy adults
C
Modest effects in deficient/pathological populations; not consistent in healthy carnitine-replete adults
Most overstated application; carnitine is not rate-limiting for fat oxidation in healthy adults
LCNC/Any
General exercise performance in healthy adults
C
Inconsistent; some sports-specific claims; not broadly supported
Form-specific claims may be valid (LCLT recovery); generic performance enhancement overstated
Form
Standard Dose
Timing
Route
Primary Goal
Notes
L-Carnitine (LCNC)
1-3 g/day divided doses
With meals (food increases absorption)
Oral
Male infertility; cardiac support; dialysis deficiency; general metabolism
Most bioavailability: fasted, but GI tolerance better with food. 1g elemental from 5g LCLT.
Acetyl-L-Carnitine (ALCAR)
500 mg - 2 g/day divided doses
Morning + midday preferred (can be mildly stimulating); away from evening
Oral
Cognitive support; neuroprotection; neuropathy; mitochondrial aging
May cause mild alertness; not evening dose. If using for neuropathy use higher end (1.5-3g/day per trials).
L-Carnitine L-Tartrate (LCLT)
1.5-3 g/day (delivers ~1-2g elemental carnitine)
Around exercise (pre/post workout)
Oral
Exercise recovery; muscle damage; androgen receptor upregulation
Fastest absorption form — use the post-exercise window specifically. 2g used in Volek 2002.
Propionyl-L-Carnitine (PLCAR)
1-3 g/day divided doses
With meals
Oral
Peripheral artery disease; vascular; intermittent claudication; erectile function
Long course required for PAD benefits (8-12 weeks minimum in RCTs). Requires physician supervision for PAD.
Vegans and vegetarians: carnitine pools are 25-50% lower than omnivores; most likely to benefit from any form of carnitine supplementation; lower TMAO risk because plant-based diet changes gut microbiome toward less TMA-producing bacteria. General recommendation: L-carnitine 500-1000 mg/day or ALCAR for cognition. Elderly adults: carnitine synthesis and dietary intake decline with age; carnitine deficiency more common; ALCAR most appropriate for cognitive and mitochondrial aging goals. Chronic kidney disease (pre-dialysis): carnitine deficiency develops progressively; physician-supervised carnitine supplementation is appropriate with advancing CKD stages. Athletes: LCLT for recovery and potential AR upregulation benefits; lower TMAO concern due to enhanced systemic carnitine utilization.
Partially true, mostly wrong as applied. Carnitine is essential for fat oxidation — this is established biochemistry. But in carnitine-replete healthy adults, additional carnitine does not meaningfully increase fat oxidation because transport capacity is not the bottleneck. Fat oxidation rate in healthy adults is primarily regulated by caloric balance, hormonal milieu (insulin levels, catecholamines), exercise intensity, and total fatty acid availability — not by transport capacity when carnitine is adequate. Fat oxidation is enhanced by carnitine primarily in states of carnitine deficiency (hemodialysis, vegetarians, CKD, elderly) or when combined with specific physiological states that create transport demand. The supplement market conflates 'carnitine is required for fat burning' (true) with 'more carnitine means more fat burning in healthy people' (false in most cases).
If this means plain L-carnitine (LCNC), the wrong form is being used. Plain L-carnitine does not meaningfully cross the blood-brain barrier due to its zwitterionic, highly water-soluble chemistry. The 21-RCT meta-analysis showing cognitive benefits used ALCAR — the acetylated form that crosses the BBB. ALCAR-specific mechanisms (acetylcholine precursor, NGF receptor upregulation, brain oxidative stress reduction) are not available from plain carnitine. Aged rat head-to-head studies confirm: ALCAR reduces brain lipid peroxidation and oxidized nucleotides; plain carnitine at the same dose does not. The community practice of buying plain 'L-carnitine' for cognitive goals is pharmacologically incorrect.
The cardiac evidence is real but context-specific. DiNicolantonio's 2013 meta-analysis showing 27% mortality reduction is in patients with acute MI or established heart failure — people with pathological carnitine depletion in ischemic myocardium. The post-MI context is biologically different from healthy cardiovascular optimization: ischemia depletes carnitine in the affected muscle; repletion restores function. Extrapolating these benefits to healthy adults as 'cardiovascular support' ignores both the context-specificity of the benefit and the TMAO cardiovascular risk that applies at the population level. The TMAO-CAD Mendelian randomization signal (OR 1.07 in men) does not show benefit — it shows potential harm. The risk-benefit equation in healthy adults with normal carnitine status is quite different from post-MI patients.
The most consequential misconception in carnitine use. The four forms have distinct pharmacological profiles with non-interchangeable mechanisms and evidence bases. Form matters: for cognitive goals, only ALCAR; for PAD, only PLCAR; for recovery/AR, LCLT was specifically studied; for fertility/cardiac/dialysis, plain L-carnitine is appropriate. Trials that show no cognitive benefit from 'carnitine' typically used plain L-carnitine — a non-BBB-crossing form for a BBB-dependent goal. These negative results are not failures of the carnitine hypothesis; they are failures of form selection.
Montgomery SA, Thal LJ, Amrein R. (2003). Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. International Clinical Psychopharmacology. 18(2):61-71. [21-RCT meta-analysis; significant cognitive improvement vs placebo; the foundational ALCAR cognitive aging evidence.]
Cochrane review on ALCAR for neuropathic pain (updated 2021). Summarizing multiple RCTs of ALCAR 1,500-3,000 mg/day in peripheral and diabetic neuropathy. Significant pain reduction and nerve conduction improvement. [Cochrane-level evidence for ALCAR in neuropathy.]
Volek JS, Kraemer WJ, Rubin MR, Gómez AL, Ratamess NA, Gaynor P. (2002). L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress. American Journal of Physiology: Endocrinology and Metabolism. 282(2):E474-482. [Double-blind crossover; LCLT 2g/day; significantly higher androgen receptor concentration in muscle biopsy post-exercise; reduced muscle damage markers; the foundational LCLT/AR evidence.]
Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. (1992). Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Journal of the American College of Cardiology. 26(6):1411-1416. [Key PLCAR PAD trial; approximately 90m improvement in walking distance; multicenter, double-blind; foundational evidence for vascular application.]
DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. (2013). L-Carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proceedings. 88(6):544-551. [27 RCTs, n=3,629 post-MI/heart failure; 27% all-cause mortality reduction; 40% ventricular arrhythmia reduction; 25% angina reduction; major cardiac evidence review.]
Systematic review and meta-analysis of L-carnitine supplementation for male infertility (2020). Multiple RCTs; improved sperm motility, concentration, and pregnancy rates in idiopathic infertility. [Grade B evidence for male fertility application.]
Koeth RA, Wang Z, Levison BS et al. (2013). Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine. 19(5):576-585. [The foundational carnitine-TMAO-atherosclerosis paper; gut microbiome conversion; pro-atherogenic mechanisms; the paper that changed the carnitine cardiovascular narrative.]
Zhao JV, Burgess S, Fan B, Smith GD. (2022). L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study. BMC Medicine. 20(1):208. PMC9434903. [Mendelian randomization; OR 1.07 for CAD with genetically predicted higher carnitine; sex-specific (men but not women); supports potential harm, not benefit, at population level for cardiovascular outcomes.]
L-Carnitine has genuine, Grade B clinical evidence for multiple specific indications — but the form matters enormously, the population matters enormously, and the most marketed application (fat loss in healthy adults) has the weakest evidence.
The central tension resolved: L-Carnitine's evidence base is large and real, but it is concentrated in populations with pathological carnitine depletion or specific conditions responsive to the mechanism. ALCAR for neuropathy and cognitive aging in elderly/MCI populations — Grade B. PLCAR for peripheral artery disease — Grade B. LCLT for exercise recovery and androgen receptor upregulation — Grade B. Plain L-carnitine for male infertility and post-MI cardiac outcomes — Grade B. FDA-approved for dialysis deficiency — Grade A. Fat loss in healthy, carnitine-replete adults — Grade C at best. The form-function matching error is ubiquitous: most community users buy generic plain L-carnitine for goals that require specific forms (ALCAR for cognition, PLCAR for circulation, LCLT for recovery). The TMAO cardiovascular signal is real and adds a modest but genuine risk consideration for long-term plain L-carnitine supplementation in healthy men with cardiovascular risk factors.
— End of L-Carnitine —
THE PEPTIDE BIBLE | L-Carnitine | For Research & Educational Purposes Only
L-Carnitine: NOT a peptide — quaternary ammonium compound synthesized from lysine + methionine. MW 161.20 Da. C₇H₁₅NO₃. Zwitterionic. Conditionally essential nutrient. THE FOUR FORMS: (1) L-Carnitine (LCNC) — base form; poor BBB crossing; fat transport; fertility; cardiac; dialysis; (2) Acetyl-L-Carnitine (ALCAR) — BBB-crossing; acetylcholine precursor; NGF receptor upregulation; brain antioxidant; cognitive and neuroprotective applications only; (3) L-Carnitine L-Tartrate (LCLT) — fastest absorption; exercise recovery; androgen receptor upregulation (Volek 2002); (4) Propionyl-L-Carnitine (PLCAR) — propionyl → Krebs cycle + NO synthesis; peripheral vascular; PAD. FORM-FUNCTION RULE: cognitive = ALCAR only; PAD = PLCAR only; recovery/AR = LCLT; fertility/cardiac/dialysis = LCNC; fat loss = any form (but Grade C). MECHANISM: LCNC/all forms — CPT-I/CACT system transports LCFA across inner mitochondrial membrane for beta-oxidation; carnitine is the gatekeeper. ALCAR additionally: BBB crossing; acetyl-CoA → acetylcholine precursor; cardiolipin support; NGF receptor upregulation; brain oxidative stress reduction. PLCAR: propionyl → Krebs cycle substrate; eNOS/NO synthesis; vascular endothelial support. LCLT: same as LCNC + fastest absorption for post-exercise window. EVIDENCE: ALCAR cognitive aging/MCI (B — Montgomery 2003, 21-RCT meta-analysis); ALCAR neuropathy (B — 2021 Cochrane); LCLT exercise recovery/AR upregulation (B — Volek 2002); PLCAR PAD (B — meta-analysis, ~90m walking improvement); LCNC male infertility (B — 2020 meta-analysis); LCNC post-MI cardiac (B — DiNicolantonio 2013, 27 RCTs, 27% mortality reduction); LCNC hemodialysis deficiency (A — FDA-approved); fat loss in healthy adults (C — modest, inconsistent). TMAO CONCERN: gut bacteria → L-carnitine → TMA → liver FMO3 → TMAO → pro-atherogenic (Koeth 2013 Nature Medicine); Mendelian randomization OR 1.07 for CAD (men > women; Zhao 2022 BMC Medicine); ALCAR has lower TMAO impact due to faster absorption. FDA STATUS: L-Carnitine injection (Carnitor) FDA-approved for dialysis carnitine deficiency. ALCAR/LCLT/PLCAR: dietary supplements. WADA: not prohibited. DOSING: ALCAR 500-2,000 mg/day (morning); LCLT 2g/day (around exercise); PLCAR 1-3g/day (with meals); LCNC 1-3g/day (with meals). VEGANS/VEGETARIANS: 25-50% lower carnitine pools; most likely to benefit from supplementation. KEY MISCONCEPTIONS: (1) any form = any effect (false — form determines mechanism); (2) carnitine burns fat in healthy people (only in deficient populations); (3) cardiac benefits extrapolate to healthy adults (mostly pathological context evidence).
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.